Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
作者： Makoto Maemondo , Akira Inoue , Kunihiko Kobayashi , Shunichi Sugawara , Satoshi Oizumi
关键词:
摘要: In the planned interim analysis of data for first 200 patients, progression-free survival was significantly longer in gefitinib group than standard-chemotherapy (hazard ratio death or disease progression with gefitinib, 0.36; P<0.001), resulting early termination study. The had a median (10.8 months, vs. 5.4 months chemotherapy group; hazard ratio, 0.30; 95% confidence interval, 0.22 to 0.41; as well higher response rate (73.7% 30.7%, P<0.001). overall 30.5 and 23.6 (P = 0.31). most common adverse events were rash (71.1%) elevated amino transferase levels (55.3%), group, neutropenia (77.0%), anemia (64.6%), appetite loss (56.6%), sensory neuropathy (54.9%). One patient receiving died from interstitial lung disease. CONCLUSIONS First-line patients advanced non–small-cell cancer who selected on basis EGFR mutations improved survival, acceptable toxicity, compared standard chemotherapy. (UMIN-CTR number, C000000376.)
elsevier.com
researchgate.net 
reteoncologicaumbria.org 参考文章(31)
Shoji Kudoh, Harubumi Kato, Yutaka Nishiwaki, Masahiro Fukuoka, Kouichiro Nakata, Yukito Ichinose, Masahiro Tsuboi, Soichiro Yokota, Kazuhiko Nakagawa, Moritaka Suga, Haiyi Jiang, Yohji Itoh, Alison Armour, Claire Watkins, Tim Higenbottam, Fredrik Nyberg, , Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. American Journal of Respiratory and Critical Care Medicine. ,vol. 177, pp. 1348- 1357 ,(2008) , 10.1164/RCCM.200710-1501OC
H Asahina, , K Yamazaki, I Kinoshita, N Sukoh, M Harada, H Yokouchi, T Ishida, S Ogura, T Kojima, Y Okamoto, Y Fujita, H Dosaka–Akita, H Isobe, M Nishimura, A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. British Journal of Cancer. ,vol. 95, pp. 998- 1004 ,(2006) , 10.1038/SJ.BJC.6603393
Joan H. Schiller, David Harrington, Chandra P. Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H. Johnson, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 346, pp. 92- 98 ,(2002) , 10.1056/NEJMOA011954
Tomoaki Tanaka, Masaru Matsuoka, Akihisa Sutani, Akihiko Gemma, Makoto Maemondo, Akira Inoue, Shoji Okinaga, Makoto Nagashima, Satoshi Oizumi, Kazutsugu Uematsu, Yoshiaki Nagai, Gaku Moriyama, Hitoshi Miyazawa, Kenji Ikebuchi, Satoshi Morita, Kunihiko Kobayashi, Koichi Hagiwara, Frequency of and variables associated with the EGFR mutation and its subtypes International Journal of Cancer. ,vol. 126, pp. 651- 655 ,(2010) , 10.1002/IJC.24746
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
A Sutani, Y Nagai, K Udagawa, Y Uchida, N Koyama, Y Murayama, T Tanaka, H Miyazawa, M Nagata, M Kanazawa, K Hagiwara, K Kobayashi, Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp British Journal of Cancer. ,vol. 95, pp. 1483- 1489 ,(2006) , 10.1038/SJ.BJC.6603466
Martin M. Oken, Richard H. Creech, Douglass C. Tormey, John Horton, Thomas E. Davis, Eleanor T. McFadden, Paul P. Carbone, Toxicity and response criteria of the Eastern Cooperative Oncology Group American Journal of Clinical Oncology. ,vol. 5, pp. 649- 655 ,(1982) , 10.1097/00000421-198212000-00014
Shinichi Toyooka, Toshimi Takano, Takayuki Kosaka, Katsuyuki Hotta, Keitaro Matsuo, Shuji Ichihara, Yoshiro Fujiwara, Junichi Soh, Hiroki Otani, Katsuyuki Kiura, Keisuke Aoe, Yasushi Yatabe, Yuichiro Ohe, Tetsuya Mitsudomi, Hiroshi Date, Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma Cancer Science. ,vol. 99, pp. 303- 308 ,(2008) , 10.1111/J.1349-7006.2007.00688.X
Akira Inoue, Takuji Suzuki, Tatsuro Fukuhara, Makoto Maemondo, Yuichiro Kimura, Naoto Morikawa, Hiroshi Watanabe, Yasuo Saijo, Toshihiro Nukiwa, Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. Journal of Clinical Oncology. ,vol. 24, pp. 3340- 3346 ,(2006) , 10.1200/JCO.2005.05.4692
Rafael Rosell, Teresa Moran, Cristina Queralt, Rut Porta, Felipe Cardenal, Carlos Camps, Margarita Majem, Guillermo Lopez-Vivanco, Dolores Isla, Mariano Provencio, Amelia Insa, Bartomeu Massuti, Jose Luis Gonzalez-Larriba, Luis Paz-Ares, Isabel Bover, Rosario Garcia-Campelo, Miguel Angel Moreno, Silvia Catot, Christian Rolfo, Noemi Reguart, Ramon Palmero, José Miguel Sánchez, Roman Bastus, Clara Mayo, Jordi Bertran-Alamillo, Miguel Angel Molina, Jose Javier Sanchez, Miquel Taron, None, Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer The New England Journal of Medicine. ,vol. 361, pp. 958- 967 ,(2009) , 10.1056/NEJMOA0904554